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Background: SURF1 deficiency, a monogenic mitochondrial disorder, is the most frequent cause of cytochrome c
oxidase (COX) deficient Leigh syndrome (LS). We report the first natural history study of SURF1 deficiency.
Methods: We conducted a multi-centre case notes review of 44 SURF1-deficient patients from ten different UK
centres and two Australian centres. Survival data for LRPPRC-deficient LS and nuclear-encoded complex I-deficient
LS patients were obtained from previous publications. The survival of SURF1-deficient patients was compared with
these two groups using Kaplan-Meier survival analysis and logrank test.
Results: The majority of patients (32/44, 73%) presented in infancy (median 9.5 months). Frequent symptoms were
poor weight gain (95%, median age 10 months), hypotonia (93%, median age 14 months), poor feeding/vomiting
(89%, median age 10 months), developmental delay (88%, median age 14 months), developmental regression (71%,
median age 19 months), movement disorder (52%, median age 24 months), oculomotor involvement (52%, median
age 29 months) and central respiratory failure (78%, median age 31 months). Hypertrichosis (41%), optic atrophy
(23%), encephalopathy (20%), seizures (14%) and cardiomyopathy (2%) were observed less frequently.
Lactate was elevated in CSF (mean 4.3 mmol/L) in all patients (30/30) and in blood (mean 4.4 mmol/L) in 31/38
(81%). Fibroblast COX activity was universally decreased (25/25). Normal COX histochemistry was noted in 30% of
biopsies, whereas muscle COX activity was reduced in 96% (25/26). Neuroimaging demonstrated lesions
characteristic of LS in 28/33 (85%) and atypical findings in 3/33 (9%). Peripheral neuropathy was present in 13/16
(81%) (demyelinating 7/16, axonal 2/16). Kaplan-Meier analysis demonstrated that SURF1-deficient patients
experience longer survival (median 5.4 years, p < 0.001) compared to LRPPRC deficiency (median 1.8 years) and
nuclear-encoded complex I-deficient LS (median 1.6 years). Survival >10 years was observed in 7 patients, 6 of these
patients did not experience neurological regression. The most frequent mutation was c.312_320del10insAT. Five
novel mutations (c.468_469delTC, c.799_800delCT, c.575G>A (p.Arg192Gln), c.751+5G>A and c.752-2A>G) were
identified.
Conclusions: SURF1-deficient patients have a homogeneous clinical and biochemical phenotype. Early recognition
is essential to expedite diagnosis and enable prenatal diagnosis.
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SURF1 deficiency is a recessively inherited mitochon-
drial disorder and is the most frequent cause of Leigh
syndrome (LS) associated with cytochrome c oxidase
(COX, complex IV) deficiency. COX is the fourth com-
plex of the mitochondrial oxidative phosphorylation
(OXPHOS) system where sequential electron transfer is
coupled to proton pumping by complexes I-IV. The
electrochemical gradient generated is ultimately used by
complex V (ATP synthase) to synthesise ATP from ADP
and inorganic phosphate. A number of assembly factors
are required for the intricate biogenesis of the COX
holoenzyme and studies in Paracoccus denitrificans and
Saccharomyces cerevisiae have identified SURF1 as a key
player in the early assembly of COX [1,2].
Due to their clinical and genetic heterogeneity, mito-
chondrial diseases are often a diagnostic challenge. LS, a
fatal subacute necrotising encephalomyelopathy, is a
genetically heterogeneous mitochondrial disorder which
can be associated with any OXPHOS deficiency [3].
Since SURF1 mutations were linked to COX deficiency
and LS in 1998 [4,5] isolated case reports and mutation
series have been reported [6,7]. However a collective de-
scription depicting the natural history with biochemical
and radiological features of this disease has not yet been
published. The disease features of SURF1 deficiency are
not widely recognized by paediatricians and a clear un-
derstanding of the clinical continuum of the disease is
important to improve diagnosis of this condition. Af-
fected families often enquire about prognosis, but there
is limited data in the literature to provide prognostic in-
formation. Well-documented natural history studies are
also an invaluable aid to planning future clinical trials.
We sought to characterise the phenotypic and geno-
typic spectrum of SURF1 deficiency, to provide survival
data in a large cohort, and highlight clinical predictors
of longer survival. We also report 5 novel mutations and
review all the cases published in the literature.
Materials and methods
We conducted a multi-centre case notes review of all
patients diagnosed since 1998, when SURF1 mutations
were first linked to LS. All SURF1-deficient patients
were identified through the NHS Specialized Services-
funded mitochondrial molecular diagnostic laboratory in
Oxford which provides a national diagnostic service for
SURF1 in the UK, and through the major Australasian
paediatric diagnostic centre (Murdoch Childrens Re-
search Institute, Melbourne). All subjects with a con-
firmed genetic diagnosis of SURF1 deficiency, defined as
two pathogenic variants in the SURF1 gene, were consid-
ered eligible. We also included patients who died before
the SURF1 gene was identified, if subsequent analysis of
stored samples revealed two pathogenic SURF1 mutations.Where stored samples were unavailable, we included de-
ceased patients if they had an affected sibling with a con-
firmed SURF1 mutant genotype and a similar disease
course.
Clinical data including the age-of-onset of symptoms,
neuroimaging, nerve conduction studies, muscle hist-
ology and histochemistry, blood lactate, CSF lactate, and
respiratory chain enzyme (RCE) activities in muscle and
cultured skin fibroblasts, were collected using a structured
questionnaire completed by the responsible clinician at
each centre. The questionnaire (Additional file 1) was de-
veloped and tested in a pilot study conducted at Great
Ormond Street Hospital, London, UK on ten patients with
genetically confirmed SURF1 deficiency.
All genetic studies were performed with informed con-
sent of parents/legal guardians of the patients. Ethical
approval for the study was obtained from the National
Research Ethics Committee London Bloomsbury, UK
and the Royal Children’s Hospital Human Research Eth-
ics Committee, Melbourne, Australia (HREC 32188A).
Systematic literature review
To identify previously published cases a systematic lit-
erature search was conducted in PubMed in January
2013 using the search terms “SURF1”, “SURF-1”, “Leigh
syndrome”, “cytochrome c oxidase deficiency”, “complex
IV deficiency”, and “Cox deficiency”. The search was
limited to studies in humans published after 1.1.1998
(the year SURF1 deficiency was first described). There
were no language restrictions. Of 2135 identified re-
cords, 1969 were excluded based on review of titles, 110
were excluded on the basis of abstracts, and 56 full-text
records were retrieved. Of these, 43 records describing
129 cases with SURF1 deficiency were reviewed. Bibliog-
raphies were searched manually for additional records.
The cases were used to ascertain previously identified
phenotypes and genotypes, to draw phenotype and geno-
type comparisons between our cohort and previously
published cases and for Kaplan-Meier survival analysis.
These cases were not included in our natural history
analysis, as data was incomplete and the chronological
onset of symptoms was not available in many of the
published cases. Authors were contacted and raw data
was obtained for survival rates of LRPPRC-deficient LS
patients [8] and nuclear-encoded complex I-deficient LS
patients [9].
Statistical analysis
Kaplan-Meier survival analysis was used to compare sur-
vival rates for the SURF1 deficiency, LRPPRC-deficient
LS and nuclear-encoded complex I-deficient LS patients.
Mortality rates were compared using the log rank test.
Statistical analysis was performed using Stata 12.1 soft-
ware (Stata, College Station, Tex).
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Demography
We identified 57 patients with SURF1 disease born be-
tween 1976 and 2010, diagnosed at ten centres in the
UK (n = 52) and two centres in Australia (n = 5). Geno-
types were established in 54 patients and 3 deceased pa-
tients were assumed to have the same genotype as their
affected sibling with SURF1 deficiency since they had a
similar disease course. Detailed clinical data were avail-
able in 45 patients. It was not possible to trace clinical
records and/or the responsible clinician in the remaining
12 cases. One patient from a consanguineous pedigree
was found to have genetically confirmed Zellweger syn-
drome in addition to SURF1 disease (homozygous
c.799_800delCT) and was excluded from further ana-
lyses. The study group consisted of 44 patients (24
males, 55%) from 37 pedigrees, with 10 (23%) patients
from consanguineous families. Of these, 4 cases (cases 1b,
30, 35 and 36 in Table 1) have been published [3,10,11].
White Europeans formed the largest ethnic group (n = 20,
45%) followed by Bangladesh Bengali (n = 5, 11%), Indian
Gujarati (n = 5, 11%) and Pakistani (n = 4, 9%). Other eth-
nicities included Turkish Cypriot (n = 2), Chinese (n = 1),
Sri Lankan (n = 1) and six cases where the ethnicity was
not specified.
Initial symptoms
The median age for the onset of first symptoms was
9.5 months (range 0–60 months) and the majority of the
patients presented in the first year (32/44, 73%). The most
frequently noted initial symptoms were poor feeding/
vomiting (frequently attributed to gastro-oesophageal re-
flux) and poor weight gain (Table 2). The neonatal period
was uneventful in the majority of patients (41/44, 93%) ex-
cept in two patients with feeding problems and one pa-
tient with hypotonia. Developmental regression, defined
as a loss of cognitive or motor skills, was the initial symp-
tom in 3/44 (7%) patients. Most patients (26/44, 59%)
presented with a combination of gastro-intestinal symp-
toms, poor weight gain and hypotonia. Three patients
who underwent a general anaesthetic in the first two
months experienced significant problems during the re-
covery period. One patient (case 30), who had surgery for
transposition of the great arteries on day 9, developed per-
sistent vomiting and required enteral feeding. The second
patient (case 26) became hypotonic following surgery for
pyloric stenosis at 8 weeks. The third patient (case 4) de-
veloped a movement disorder after an upper gastro-
intestinal endoscopy.
Major clinical features
Review of 44 cases with SURF1 deficiency revealed that
32 patients met the criteria for Leigh syndrome [3] and
12 patients were classified as “Leigh-like” due to atypicalor normal radiological features or where neuroimaging
was not available. The development of clinical features
over time is demonstrated in Figure 1. Poor weight gain
and hypotonia were the most prevalent symptoms, and
tended to be preceded by gastro-intestinal symptoms
such as poor feeding/vomiting (Figure 1). Long term en-
teral feeding was required in 21/44 (48%). Developmen-
tal regression (median age-of-onset 19 months) was
noted in 27/38 (71%) cases and was precipitated by an
intercurrent viral infection in 12 patients.
Hypertrichosis was reported in 18/44 (41%) patients.
There was no significant correlation between the pres-
ence of hypertrichosis and lactic acidosis. Nystagmus
and ophthalmoplegia were found in 25/42 (60%) and 22/
42 (52%) patients, respectively, and occurred later (me-
dian age-of-onset 29 months). Movement disorder was
noted in 22/42 (52%) patients (median age-of-onset
2 years) with an isolated intention tremor in 13 patients,
choreoathetoid movements in 3, and dystonia in 2, while
4 patients demonstrated a combination of these abnor-
mal movements. Only 6/44 (14%) patients reported sei-
zures (generalised tonic clonic 5, myoclonic 1) and 4 of
these patients were from Australia. Other less frequent
clinical features included optic atrophy in 10/44 (23%),
encephalopathy in 9/44 (20%) and hypertrophic cardio-
myopathy in 1/44 (2%). None of the patients were
reported to have pigmentary retinopathy or sensori-
neural deafness.
Biochemical data
CSF lactate was elevated in all subjects who had this mea-
sured (mean 4.3, range 2.5-8.6 mmol/L, normal <2 mmol/L).
Metabolic acidosis was present in 21/33 (64%) patients
(mean bicarbonate level 14.7, range 10–17 mmol/L). 31/38
(81%) patients had elevated blood lactate (mean 4.4, range
2.3-7.3 mmol/L) (Table 3). Fibroblast COX activity was
found to be low in all subjects who were tested (25/25,
100%) and ranged from levels below the detection limit of
the assay, to 57% of the lower limit of the reference range
(reference range 30–90 nmol/mg protein/min).
Muscle biopsy
We analysed the histology and RCE findings of all pa-
tients where a muscle biopsy was performed (n = 33).
Lipid content was increased in 15/33 (46%) of biopsies
and type 1 fibre predominance was noted in 8 biopsies.
COX histochemistry demonstrated absent COX in 9
(27%) biopsies and reduced COX staining in 14 (42%)
biopsies. Ten (30%) of the biopsies were reported to
have normal COX histochemistry with uniform staining
of all fibres. RCE activities were measured in 28 biopsies.
Two post-mortem biopsies were excluded since post-
mortem delay may have resulted in artefactual loss of
RCE activities. An isolated decrease of COX activity was
Table 1 Clinical features and genotypes of 44 patients with SURF1 deficiency
Case Gender Consanguinity Clinical features Age at
onset*
(months)
Age at
death*
(months)
Skeletal muscle
histology/
histochemistry
Muscle
COX
Fibroblast
COX activity
Abnormal regions
on neuroimaging
SURF1 Mutations
1a M Yes PF/V, PW, nystagmus, RF 8 2y 1 m NA NA 29% of LLR Cp, tectal plate, PAG,
Icp, Ion, Dt, corticospinal
tracts
Homo c.792_793delAG
1b F Yes PW, hypotonia, DR, DD,
hypertrichosis, nystagmus,
RF
9 3y T1FP, increased
lipid
Low UD Leukoencephalopathy:
WM, posterior limbs of
IC, Cc, Dt, cerebellar WM
Homo c.792_793delAG
2 F No Ataxia, hypotonia, nystagmus,
ophthalmoplegia, PW, tremor
18 Alive 12y Smaller T1 fibres Low 19% of LLR Pu, Me, Ico c.240+1G >T, c.575G>A
3 F No DD, hypotonia, nystagmus,
PW, tremor, ophthalmoplegia,
ataxia
birth Alive 19y Normal Low 37% of LLR Mb, pons c.312_320del10insAT,
c.751+5G>A
4 F No PF, movement disorder, PW,
DD, RF
7 16 NA Low 57% of LLR NA Homo c.312_320del10insAT
5a M No PF, ataxia, nystagmus.
ophthalmoplegia, tremor,
PW, DR, RF
10 5y 2 m Absent COX,
increased lipid
Low UD Dt, Cd, Mb, Me Homo c.516-2A>G
5b M No PF/V DD, DR, RF 3 days 20 Increased lipid NA NA At 1y: normal Homo c.516-2A>G
6 M No V, PW, hypotonia, DR,
ophthalmoplegia, ataxia,
encephalopathy
9 21 Increased lipid,
reduced COX
NA 12% of LLR Dt, dorsal BS, Cp, STh Homo c.324-11T>G
7 M No V, PW, DR, tremor, nystagmus,
hypotonia, ophthalmoplegia,
ataxia
10 4y Increased lipid NA 27% of LLR Th, Cd, GP BS,
cerebellum
Homo c.312_320del10insAT
8a F No Hypertrichosis, DD, ataxia,
hypotonia, nystagmus,
ophthalmoplegia,
encephalopathy, PF, OA, RF
9 11y 9 m Reduced COX,
T1FP, increased
lipid
NA UD CT brain: GP and
cerebellar atrophy
Homo c.516-2A>G
8b F No V, DD, PW, hypertrichosis,
hypotonia, nystagmus,
ophthalmoplegia, ataxia, RF
10 6y 6 m NA NA NA CT brain: normal Homo c.516-2A>G
9a M No V, PW, DD nystagmus,
ophthalmoplegia, hypotonia
2 24 m Increased lipid,
reduced COX.
NA 27% of LLR CT brain: normal Homo c.312_320del10insAT
9b F No Hypotonia, PF/V, PW, DD,
hypertrichosis, motor delay,
ophthalmoplegia, RF, OA
1.5 4y NA NA NA CT brain: widened
subarachnoid spaces
Homo c.312_320del10insAT
10 M Yes Hypotonia, PF/V, DD,
nystagmus, PW, ataxia, RF
4 24 m T1FP Low 50% of LLR NA Homo c.516-2A>G
11 F Yes DD, DR, PF/V, PW, tremor,
OA, PW, hypotonia,
nystagmus, ataxia, RF
9 7y 1 m Absent COX
increased
lipid, T1FP
NA 7% of LLR Mb, Dt, Cd, GP Homo c.751C>T
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Table 1 Clinical features and genotypes of 44 patients with SURF1 deficiency (Continued)
12 M No PF/V, DD, DR, hypotonia,
encephalopathy, PW, RF
6 13 m NA NA NA Cd, Pu, BS Homo c.312_320del10insAT,
c.688C>T
13a F Yes DD, DR, PF/V, nystagmus,
dystonia, PW, Sz,
hypertrichosis, RF
12 5y 5 m T1FP, Reduced
COX
Low 53% of LLR Me, Cc, cerebellar
atrophy, multicystic
changes in peritrigonal
regions, posterior limbs
of IC
Homo c.324-11 T>G
13b F Yes PF/V, PW, hypotonia, DD, DR 15 Outcome
unknown
NA Low NA NA Homo c.324-11 T>G
14 F Yes DD, DR, hypotonia, PF/V,
chorea, PW, nystagmus
18 Outcome
unknown
Reduced COX,
increased lipid
Low UD BG, BS, long tracts Homo c.792_793delAG
15 M No Hypotonia, DD, DR, dystonia,
ophthalmoplegia, PF/V, RF
2y 6 m 4y 6 m Reduced COX,
T1FP
Low UD BS, Calcification of
Dt, Cd, GP
Homo c.312_320del10insAT
16 M Yes PF/V, PW, hypotonia, DD, DR,
encephalopathy, RF
9 18 m Reduced COX. Low 17% of LLR BS, Dt, SN, Pu, GP, Cd,
Cc, cystic changes in
Dt, BG and central WM
Homo c.324-11T>G
17 M No Short stature, ataxia, PW,
hypertrichosis, nystagmus, DD
5y Alive 15y Increased lipid,
reduced COX
Low NA Dt and cerebellar
atrophy
Homo c.312_320del10insAT
18 F Yes PF/V, DR, PW, DD, hypotonia,
tremor, dystonia, OA,
ophthalmoplegia
10 8y 9 m Absent COX T1FP Low 40% of LLR Leukoencephalopathy:
WM abnormalities in
cerebral hemispheres
and cerebellum
Homo c.833+1G>A
19 M No Hypotonia, PF/V, PW,
choreoathetoid
movements, dystonia, DR, RF
10 3y 6 m Reduced COX T1FP Low NA Cd, Cd, GP Cp, SN. Homo c.312_320del10insAT
20 M No Hypotonia, apnoeic episodes,
motor delay, ataxia, DR, DD,
tremor, hypertrichosis,
dystonia, PF/V, PW, RF
ophthalmoplegia, nystagmus,
hypertrichosis
10 Alive 16y Reduced COX Low NA At 1y: normal Homo c.704C>T
21a M No V, PW, generalized hypotonia,
nystagmus, ophthalmoplegia,
DD, encephalopathy, RF
10 2y 3 m Absent COX,
increased lipid
Low 23% of LLR Pu, ventral Me, cervico-
medullary region
Homo c.792_793delAG
21b M No PF/V, PW, DD, DR, hypotonia,
OA, ophthalmoplegia,
nystagmus, hypertrichosis, RF
9 2y 5 m NA NA NA NA Homo c.792_793delAG
22 M No DD, DR, PW, ataxia, dysarthria,
choking episodes, V,
hypotonia, nystagmus,
hypertrophic cardiomyopathy
4y 3 m Outcome
unknown
Absent COX Low NA Deep grey matter
involvement of
cerebellum, Mb, Pu
c.240+1G>T, c.574C>T
23 F No PF/V, DR, DD, PW, hypotonia,
nystagmus, tremor, dystonia,
15 21 m Absent COX Low NA Cc, Mb, BS, GP Homo c.312_320del10insAT
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Table 1 Clinical features and genotypes of 44 patients with SURF1 deficiency (Continued)
hypertrichosis, ophthalmoplegia,
encephalopathy, ataxia, RF
24 F No PW, V, hypertrichosis, DD,
hypotonia, ophthalmoplegia,
tremor, Sz, ataxia,
encephalopathy, RF
2 2y 10 m Absent COX Low NA Thalamic fasciculus, RN,
Mb, pons, Scp, Dt, Me,
WM tracts of spinal
cord
Homo c.324-11T>G
25a M No PW, DD, ataxia, falls, OA,
hypotonia, hypertrichosis,
ophthalmoplegia,
nystagmus, ataxia, RF
20 14y NA NA NA Me, Icp, pons. Linear
area in the periventricular
WM of both occipital
lobes
Homo c.871insT
25b M No DD, PF/V, PW, choreoathetosis,
ataxia, hypotonia, OA,
encephalopathy, ataxia, RF
24 11y Normal NA 30% of LLR Cd, GP Homo c.871insT
26 M No Hypotonia, V, PW, ophthalmoplegia,
DD, nystagmus, dyskinesia,
choreoathetoid movements, RF
2 3y 10 m Increased lipid NA UD Cd, Cd, GP, deep WM in
cerebellar hemispheres
c.312_320del10insAT,
c.240+1G>T
27 M No DD, hypotonia, PF, PW, DR, RF 10 4y 9 m Reduced COX Normal UD CT brain: BG c.845_846delCT,
c.240+1G>T
28 F No Hypotonia, PF/V, PW, hypertrichosis,
DD, DR, encephalopathy, nystagmus
3 Alive 24 m NA NA NA Me, medial aspect
of the cerebellar
peduncles, Dt, Pu,
Cp, PAG
Homo c.312_320del10insAT
29 F Yes PF, PW birth 24 m NA NA 17% of LLR NA Homo c.799_800delCT
30 M No PW, DD, tremor, hypertrichosis.
Post operative V, ophthalmoplegia,
hypotonia
9 days 5y NA Low NA Ion, inferior pons, STh,
Pu, spinocerebellar
tracts, Icp, PAG, Dt,
cerebellar WM
c.312_320del10insAT,
c.871insT
31 F No PF/V, PW, DD, DR, tremor 1.5 3y 7 m Normal Low NA RN, Scp, PAG, Dt, deep
cerebellar WM, Me, Ion,
optic radiation
Homo c.792_793delAG
32 F No PW, DD, DR, PF, hypotonia 12 2y 3 m Increased lipid Low NA Mb, pons, Me, Icp, Dt,
Cc, Cd, Pu, cerebellar
WM, STh, SN,IC, long
tracts in cervical spine
Homo c.754_755delAG
33 M No PF, PW, hypertrichosis, ataxia, DR,
hypotonia, tremors, nystagmus,
OA
14 7y 2 m Reduced COX Low 32% of LLR Me, spinal cord, Pu, SN,
IC, medullary pyramidal
decussation, middle
cerebellar peduncle
Homo c.312_320del10insAT
34 M No PW, PF/V, DD, DR, hypertrichosis,
tremor, hypotonia, ophthalmoplegia,
ataxia, RF, Sz
13 24 m Absent COX
increased lipid
Low NA Th, Mb, dorsal pons, Me c.312_320del10insAT,
c.574insCTGC
35 F No PW, PF/V, DD, DR, hypertrichosis,
hypotonia, ophthalmoplegia, OA,
nystagmus, tremor, ataxia, RF, Sz
9 2y 6 m Absent COX,
increased lipid
Post
mortem
12% of LLR Th c.312_320del10insAT,
c.751C >T
W
edatilake
et
al.O
rphanet
Journalof
Rare
D
iseases
2013,8:96
Page
6
of
13
http://w
w
w
.ojrd.com
/content/8/1/96
Table 1 Clinical features and genotypes of 44 patients with SURF1 deficiency (Continued)
36 F No PW, PF/V, DD, DR, hypertrichosis,
hypotonia, ophthalmoplegia, OA,
nystagmus, tremor, ataxia, RF, Sz,
15 7y 10 m Reduced COX,
increased lipid
Post
mortem
44% of LLR CT brain: Pu c.312_320del10insAT,
c.688C>T
37 M No PF, ophthalmoplegia ataxia,
hypotonia,Gross motor delay,
PW, DR, DD, RF, Sz,
hypertrichosis
birth 6y Reduced COX Low NA STh c.312_320del10insAT,
c. 752 -2A>G
*Age in months unless otherwise stated; a, b denote siblings; y/m years and months; NA not available.
Key to clinical and neuroimaging features: BG basal ganglia, BS Brain stem, Cc corpus callosum, Cd Caudate nucleus, COX cytochrome c oxidase, Cp cerebral peduncle, Cst corticospinal tracts, DD developmental delay,
DR developmental regression, Dt Dentate, Homo homozygous, GP Globus pallidus, IC internal capsule, Ico Inferior colliculus, Ion inferior olivary nucleus, Icp inferior cerebellar peduncle, LLR lower limit of reference
range, Mb Midbrain, Me Medulla, NA not available, PAG periaqueductal gray matter, PF poor feeding, Pu Putamen, PW poor weight gain, RF Respiratory failure, RN Red nucleus, OA optic atrophy, Sco superior colliculus,
Scp superior cerebellar peduncle, SN Substantia Nigra, STh Subthalamic nucleus, Sz Seizures, T1 type 1 muscle fibres, T1FP Type 1 muscle fibre predominance, T2 type 2 muscle fibres, Th Thalamus, UD undetectable, V
vomiting, WM white matter.
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Table 2 Initial symptoms in 44 patients with SURF1
deficiency
Initial symptoms Number of
patients (%)
Age range of initial
presentation (months)
poor feeding/vomiting 20 (46) 0-24
poor weight gain 19 (43) 1.5-20
developmental delay 10 (23) 9-51
hypotonia 9 (21) 0-10
movement disorder 3 (7) 10-24
developmental regression 3 (7) 10-18
ataxia 2 (5) 14-60
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http://www.ojrd.com/content/8/1/96found in all except one biopsy where the COX activity
was at the lower end of the reference range (COX activ-
ity/citrate synthase ratio was 0.016 (reference range
0.014-0.034).
Neuroimaging
Magnetic resonance imaging (MRI) and Computerised
tomography scan (CT) information was available for 39
subjects (33 MRI and 6 CT scans). The patterns of in-
volvement are shown in Table 3. Most MRIs showed
findings characteristic of Leigh syndrome (28/33, 85%),
with symmetrical hyperintense lesions on T2-weighted
imaging in the brainstem and/or basal ganglia (Table 3).
Two patients had normal MRI scans which were
performed at 1 year of age and follow up imaging was
not available. Two patients (one already published, [10])
had leukoencephalopathy (defined as a disorder that pre-
dominantly or exclusively affects the white matter of theFigure 1 Clinical features in 44 patients with SURF1 deficiency. The x
clinical features. Percentages denote the proportion of patients with a give
The median age of onset is indicated by the vertical line within the boxes.
values, and dots represent outliers which are ≥1.5 times the interquartile ra
included hypertrichosis (41%), optic atrophy (23%), encephalopathy (20%),brain [12]), while one patient had cerebellar atrophy and
involvement of the dentate nucleus. Six patients had CT
scans of which 3 were found to be normal and three had
bilateral symmetric hypodensities in the basal ganglia.
Peripheral nervous system
Sixteen patients had nerve conduction studies performed.
Abnormal peripheral nerve conduction was noted in
13/16 (81%) with most (7) demonstrating a demyelin-
ating neuropathy compared to an axonal neuropathy in
2 subjects. The type of neuropathy was unspecified in
4 subjects. Many (9/13, 69%) subjects showed a mixed
sensori-motor involvement whereas 2 subjects had a
pure sensory neuropathy.
SURF1 gene mutations
We identified SURF1 mutations in 57 patients; 16/57
(28%) had the homozygous c.312_320del10insAT inser-
tion/deletion, 15/57(26%) were compound heterozygotes,
12/57(21%) had homozygous splice site mutations, 10/57
(18%) had homozygous deletions, 2/57 (4%) had homozy-
gous insertions, 1/57 (2%) had homozygous missense
mutations and 1/57(2%) had homozygous nonsense
mutations. The most frequently occurring mutation in
our cohort was c.312_321del10insAT (p.Leu105X) (16
homozygous and 11 compound heterozygous). The
next most common mutations were c.792_793delAG
which occurred exclusively in Bangladesh Bengali subjects
(n = 5, 3 pedigrees) and the splice mutation c.240+1G>T
which was observed in 5 individuals, all of white European
origin. The c.792_793delAG mutation has previously onlyaxis indicates the age of onset (years) and the y axis indicates the
n clinical feature, and box-and-whisker plots show the age of onset.
Boxes represent upper and lower quartiles, whiskers represent extreme
nge from the median. Other less commonly observed features
seizures (14%) and cardiomyopathy (2%).
Table 3 Laboratory and magnetic resonance imaging
(MRI) findings in SURF1 deficiency
Laboratory or neuroimaging finding Number of patients %
Blood
Metabolic acidosis 21/33 64
Elevated lactate 31/38 81
Cerebrospinal fluid
Elevated lactate 30/30 100
Muscle
Reduced/absent COX histochemistry 23/33 70
Type I fibre predominance 8/33 24
Elevated muscle lipid content 16/33 48
Reduced muscle COX activity 25/26 96
Fibroblast
Reduced fibroblast COX activity 25/25 100
Nerve conduction studies
Peripheral neuropathy 13/16 81
MRI lesions
Midbrain 12/33 36
Pons 10/33 30
Medulla 15/33 45
Putamen 16/33 48
Globus pallidus 14/33 42
Caudate nucleus 12/33 36
Subthalamic nucleus 4/33 12
Periaqueductal grey matter 4/33 12
Olivary nuclei 3/33 9
Red nuclei 2/33 6
Cerebellar white/grey matter 6/33 18
Cerebellar atrophy 3/33 9
Dentate nucleus 13/33 39
Cerebellar peduncles 8/33 24
Leukoencephalopathy 2/33 6
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http://www.ojrd.com/content/8/1/96been described in a patient of Japanese origin [13]. Indi-
viduals of Pakistani origin had the novel c.799_800delCT
mutation or the c.324-11T>G mutation. The c.516-2A>G
mutation segregated in two different Indian Gujarati pedi-
grees and has previously only been described in one sub-
ject of unspecified mixed Caucasian Asian parenthood [7].
The c.324-11T>G genotype was observed in 4 individuals
from 2 different Pakistani pedigrees and one individual of
Indian Gujarati origin. All five patients from the Aus-
tralian cohort had at least one c.312_321del10insAT
(p.Leu105X) mutation. No specific genotype phenotype
correlation was observed. The patients surviving >10
years had varied SURF1 genotypes: one was homozy-
gous for the c.312_321del10insAT mutation, two werecompound heterozygotes, two had homozygous inser-
tions and one had a splice site mutation.
Novel pathogenic mutations
In our cohort we identified 19 SURF1 mutations (Figure 2)
in 57 patients including 5 novel pathogenic mutations
(c.468_469delTC, c.799_800delCT, c.575G>A (p.Arg192Gln),
c.751+5G>A. and c.752-2A>G).
Of the novel mutations identified, the homozygous
c.799_800delCT was found in a Pakistani family where
the patient (case 29) presented with early onset disease
from birth and died at 2 years. The novel splice site
c.751+5G>A mutation, generating an aberrant tran-
script with incorporation of 31 base pairs of intron 7
into a proportion of mature mRNAs, was found in one
subject (case 3) who was a compound heterozygote
(c.312_321del10insAT, c.751+5G>A). She had an atyp-
ical milder clinical course with longer survival. Her
first concerning symptoms were at 16 months when
she was noted to have mild motor delay and ataxia but
in retrospect mild hypotonia was present from birth.
She subsequently developed nystagmus and external
ophthalmoplegia. She is currently studying business
studies at 19 years of age. The novel missense muta-
tion (c.575G>A, p.Arg192Gln) was found in a 12 year
old female (case 2) with ataxia and a 4 year old male
(case 22) with developmental delay, ataxia and hyper-
trophic cardiomyopathy. This was the only patient in
the cohort with cardiomyopathy. The female patient
subsequently developed nystagmus with ophthalmople-
gia but she is currently able to ride a bicycle and play
the violin. The splice site mutation c.752-2A>G was
found in a patient (case 37) of Australian origin who
presented with irritability and poor feeding since birth.
Unfortunately clinical information was unavailable for
the patient with the homozygous c.468_469delTC
mutation.
Survival
Among the 44 patients with detailed clinical data, five
were alive at the time of writing (age range 2–19 years)
while in three patients the current vital status was not
known. Of the 36 deceased patients with known cause
of death, the cause was central respiratory failure in
29/36 (80%). Seven patients survived beyond 10 years
of age (cases 2, 3, 8a, 17, 20, 25a, 25b in Table 1). Of
these, 6 presented with neurological symptoms such as
ataxia and motor developmental delay; of note, gastro-
intestinal symptoms were not the prominent presenting
feature in these cases. Furthermore, these six patients also
did not experience developmental regression.
Literature searches identified 98 SURF1-deficient cases
with available survival data, which we pooled together
with the data from our 44 cases. In a Kaplan-Meier
Figure 2 Pathogenic mutations in the human SURF1 gene. A schematic diagram of the SURF1 gene illustrating 83 mutations reported to
date. Red: novel unreported mutations identified in this study, blue: other mutations which have been previously reported and found in this
study, black: mutations previously reported in the literature.
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http://www.ojrd.com/content/8/1/96analysis (Figure 3), we compared the survival experience of
these 142 SURF1-deficient cases to two other groups with
LS due to nuclear gene mutations. We compared the
survival of SURF1 deficiency to 56 patients with LRPPRC
deficiency [8] and 63 patients with nuclear-encoded complex
I-deficient LS/“Leigh- like” disease [9] Median survival length
was longer in patients with SURF1 deficiency (median 5.4,
25th centile 3.0, 75th centile 10 years) than in patients with
LRPPRC deficiency (median 1.8, 25th centile 1.0, 75th
centile 4 years), and nuclear-encoded complex I-deficient
LS (median 1.6, 25th centile 1.0, 75th centile 10 years)
(p < 0.001 for difference across groups; logrank test).Figure 3 Kaplan-Meier survival curves comparing SURF1 deficiency, L
Leigh/Leigh-like syndrome. Blue line: SURF1 deficient patients, n = 142 (t
green line: complex I deficient Leigh/Leigh-like syndrome n = 63 [9]. LogranAdditional cases in the literature
A systematic review of the literature revealed published
clinical data on 129 SURF1-deficient patients and mutation
data in a further 28 cases. The findings are summarised in
Additional file 1: Table S1. Features which were found in
these patients but not present in our cohort included un-
specified hepatic involvement (3 cases), renal tubulopathy
(4 cases) and facial dysmorphism (5 patients) [7,14-19].
Discussion
SURF1 deficiency is the most common single cause of
Leigh syndrome in the UK population, and carefulRPPRC-deficient LS and nuclear-encoded complex I deficient
his article and literature), red line: LRPPRC deficient patients, n = 56 [8],
k test p < 0.001.
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creased recognition and more rapid diagnosis of affected
children. The need for early genetic diagnosis can be
particularly pressing when affected families seek prenatal
diagnosis. Improving the diagnostic process relies on
well-recognised clinical features, but often there are in-
adequate numbers of patients with a single gene disorder
of mitochondrial energy metabolism to characterise phe-
notypes. We have collected a cohort of 57 SURF1-
deficient patients with comprehensive phenotypic data
on 44 patients. We found that SURF1-deficient patients
have a relatively homogenous phenotype which typically
commences in late infancy with gastro-intestinal symp-
toms, followed by episodic neurological regression, oph-
thalmoplegia, movement disorder, finally leading to
death from respiratory failure. Although there is a con-
sistent clinical phenotype, there were no clinical charac-
teristics that allowed discrimination of SURF1 deficiency
from other causes of LS, such as complex I deficiency or
complex V deficiency.
Cardiomyopathy was rare (one patient), and this ob-
servation is similar to the literature where only 2/129
cases had cardiomyopathy [14,18]. Seizure disorders also
appeared to be uncommon and were found predomin-
antly in the Australian patients which may indicate an
environmental trigger which precipitates seizures. High
temperature is unlikely to be the precipitating factor
since no seasonal variation in seizures was observed in
the cases from Australia. The low incidence of seizures
is comparable with cases described previously where
only 5% (7/129) were reported to have had seizures.
Sensorineural deafness was not found in this SURF1-
deficient cohort and is in keeping with the low occur-
rence in the literature where only two previous cases
had sensorineural deafness [14]. Three (2%) cases were
previously reported to have optic atrophy [6,18] whereas
10 (23%) of our patients were noted to have optic atrophy.
Visual and auditory signs are difficult to ascertain in
paediatric practice and may have been underdiagnosed in
many cases where formal testing was not done. Three pa-
tients who underwent an early general anaesthetic experi-
enced neurological deterioration; caution must be
exercised when considering general anaesthesia for
SURF1-deficient patients..
Although long-term survival in SURF1 deficiency is
unusual, somewhat surprisingly we found that SURF1-
deficient LS has a more favourable survival outcome
compared to complex I-deficient LS or LRPPRC-
deficient LS. Unlike SURF1 disease, LRPPRC deficiency
is complicated by acute metabolic crises, which contrib-
ute significantly to the mortality [8].
Stepwise neurological regression often precipitated by ill-
ness and other states of high-energy demand, is thought to
be part of the natural history of LS. In our cohort 6 patientssurviving >10 years did not experience developmental re-
gression which suggests that developing effective thera-
peutic manoeuvres to prevent and treat episodic
decompensation could improve the outcome in SURF1-
deficient patients. However the prevention of decompensa-
tion may be challenging in instances where an obvious
precipitant cannot be identified. It is difficult to comment
about the effect of supportive therapies in SURF1 defi-
ciency since there is insufficient treatment data available
for this cohort to draw any meaningful conclusions. Recent
candidate therapies such as EPI-743 are under evaluation
and improvement in quality of life and motor function
scores have been demonstrated in 2 SURF1-deficient pa-
tients recruited to an open-label phase 2A study [20].
We describe 5 novel mutations in addition to the 78
mutations found in the SURF1 gene so far. Approximately
80% of the mutations found in SURF1 deficiency are trun-
cating mutations resulting from aberrant splicing, frame-
shift deletions or nonsense mutations. Our study shows
segregation of specific mutations within certain ethnic
groups. The genotype distribution suggests founder effects
for some mutations such as c.311_312insATdel10 in white
Europeans and c.790_800delAG demonstrated in 3 differ-
ent Bangladesh Bengali pedigrees. Previous reports indi-
cate that c.604G > C mutation has only been reported in
Chinese individuals. We did not find a distinctive
genotype-phenotype association although earlier reports
[21] suggest missense SURF1 mutations favour a better
prognosis. It has not been possible to confirm this hypoth-
esis in our cohort since only three subjects had missense
mutations (1 homozygous, 2 compound heterozygous).
However two of these patients are currently alive at
12 years and 17 years. The 7 patients described with
milder phenotypes had varied genotypes including homo-
zygosity for the common c.312_320del10insAT, suggesting
that there are other factors which may influence survival.
We demonstrate that SURF1 deficiency has a distinct
biochemical phenotype which includes consistently ele-
vated CSF lactate, and decreased activities of COX in fi-
broblasts and muscle. Therefore when a typical clinical
presentation of LS is encountered, if fibroblast COX ac-
tivity is found to be low, targeted sequencing of the
SURF1 gene should be undertaken. If the patient is de-
teriorating rapidly it is prudent to perform a muscle bi-
opsy with initial investigations since there are no
distinctive clinical features of SURF1 deficiency which
allow discrimination from other causes of LS. Muscle
histochemistry shows uniform global reduction of COX
activity but this may be very subtle and reported as nor-
mal since many centres use a prolonged incubation for
COX histochemistry to allow maximum differentiation
between COX-positive and negative fibres. Muscle hist-
ology demonstrated non-specific abnormalities such as
lipid accumulation or fibre type disproportion (type I
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http://www.ojrd.com/content/8/1/96fibre predominance). Ragged red fibres which typically
suggest a mitochondrial DNA mutation, have only been
noted in two previous SURF1-deficient cases [14,18] and
were not found in any patients in our cohort. The clin-
ical picture encountered in SURF1 deficiency is typical
for LS, and it is only with a supportive biochemical pic-
ture such as low fibroblast and/or muscle COX activity
that SURF1 deficiency can be suspected.
Previous reviews indicate that involvement of the
subthalamic nucleus was a consistent finding on MRI in
SURF1 disease [22]. In our study only 4 (12%) had le-
sions in the subthalamic nucleus. In contrast 16/33
(48%) patients had lesions in the putamen. The specificity
of these lesions in SURF1 deficiency needs to be validated
by comparison to other groups with LS. Most (85%) MRIs
showed characteristic lesions of LS. Leukoencephalopathic
changes were an atypical finding (n = 2) but SURF1 defi-
ciency should not be overlooked in these cases [10]. The
MRI was normal in 2 subjects at 1 year of age. Normal
neuroradiology early in the disease may subsequently
evolve to abnormality on repeat imaging [18].
The presence of a demyelinating peripheral neur-
opathy has been noted in previous cases in the literature
[23,24] and here we demonstrate that while in the ma-
jority of the cases the neuropathy is indeed of a demye-
linating nature, an axonal neuropathy can be present.
Our study has several limitations. Although the study
data were collected using a standardised questionnaire this
is a retrospective study where clinical information was
obtained by reviewing medical notes/case histories of pa-
tients, many now deceased. However it is unlikely that a
large-scale prospective study will be conducted for this rare
disease. The MRIs were performed at different centres and
reviewed by different neuroradiologists which makes it dif-
ficult to ascribe specific patterns of disease. The MRI find-
ings are based on a single scan in the majority of the cases
and would only represent a snapshot of the neuroradiologi-
cal changes but not disease progression. It is often not pos-
sible to capture these changes since repeated imaging in
young children usually involves general anaesthetic with
the attendant risks of metabolic decompensation.
Conclusions
In conclusion, in contrast to other nuclear genes causing
COX deficiency such as SCO1, COX10 and COX15,
SURF1 deficiency causes a largely homogeneous pheno-
type of LS characterised by systemic COX deficiency. To
our knowledge, this is the first natural history study of
SURF1 deficiency. Here we provide the most robust clin-
ical description of the disease to date and a comprehen-
sive account of all the genotypes and phenotypes
reported so far. The prognostic and survival data in this
study is based on a larger sample size than previous co-
horts and will enable clinicians to be more confidentwhen counselling families about the disease course. Ad-
vances in our understanding of the clinical spectrum
and pathophysiology of SURF1 deficiency will be vital in
planning therapeutic interventions in the future.
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